Europe Romiplostim Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
Europe Romiplostim Market Analysis — Presence
Geographical Analysis
Click countries to exploreCountry Analysis
Europe Romiplostim Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Europe Romiplostim Total | xxxx | xxxx | xxxx | 4.5% |
| United Kingdom | xxxx | xxxx | xxxx | xxxx |
| France | xxxx | xxxx | xxxx | xxxx |
| Germany | xxxx | xxxx | xxxx | xxxx |
| Italy | xxxx | xxxx | xxxx | xxxx |
| Russia | xxxx | xxxx | xxxx | xxxx |
| Spain | xxxx | xxxx | xxxx | xxxx |
| Sweden | xxxx | xxxx | xxxx | xxxx |
| Denmark | xxxx | xxxx | xxxx | xxxx |
| Switzerland | xxxx | xxxx | xxxx | xxxx |
| Luxembourg | xxxx | xxxx | xxxx | xxxx |
| Rest of Europe | xxxx | xxxx | xxxx | xxxx |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Romiplostim Market
Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.
Romiplostim Industry News
In November 2012, Amgen announced that Nplate(TM) (romiplostim) is given marketing authorization in the European Union (EU) based on a positive judgement from the European Committee for Medicinal Products for Human Use (CHMP). For adults with splenectomized chronic immune thrombocytopenia purpura (ITP) who are not responding to alternative therapies, such as corticosteroids or immunoglobulins, the CHMP suggests Nplate. When surgery is not recommended, nplate may be used as a second line of treatment for adult non-splenectomized patients.
In October 2022, according to European Medicines Agenc, Nplate was proven to be beneficial for treating long-standing ITP in two major adult studies and a third study including children. In every study, Nplate was contrasted with a placebo, or fake treatment. The primary indicator of therapy efficacy for the patients, who had a 24-week course of treatment, was an increase in platelet count exceeding a threshold of 50 million platelets per millilitre of blood for at least six of the final eight weeks of treatment.
(Source: https://www.ema.europa.eu/en/medicines/human/EPAR/nplate)
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Company 1 | ••• | ••• | ••• | ••• |
| Company 2 | ••• | ••• | ••• | ••• |
| Company 3 | ••• | ••• | ••• | ••• |
| Company 4 | ••• | ••• | ••• | ••• |
| Company 5 | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, with a market value of USD XX million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD XX million. Increasing infrastructure developments is one of the factor anticipated to fuel the market expansion during the forecast period. Furthermore, industry cooperation, consumer trends and preferences, government laws and regulations, and technological breakthroughs are projected to propel the market growth.
- The United Kingdom romiplostim market had a market share of USD 209.27 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. The increasing government initiatives and policies to propel the market growth.
- The France romiplostim market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD XX million in 2024.
- According to Cognitive Market Research, the Germany romiplostim market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period due to the growing number of romiplostim suppliers in the Germany.
- The Italy romiplostim market is projected to witness growth at a CAGR of 3.9% during the forecast period with a market size of USD XX million in 2024.
- The Russia romiplostim market is projected to witness growth at a CAGR of 3.5% during the forecast period with a market size of USD XX million in 2024.
- The Spain romiplostim market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD XX million in 2024.
- The Luxembourg romiplostim market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD XX million in 2024.
- The Portugal romiplostim market is projected to witness growth at a CAGR of 4.3% during the forecast period with a market size of USD XX million in 2024.
- The Greece romiplostim market is projected to witness growth at a CAGR of 4.8% during the forecast period with a market size of USD XX million in 2024.
- Rest of Europe romiplostim market is projected to witness growth at a CAGR of 3.2% during the forecast period with a market size of USD XX million in 2024.
The pharmaceutical and healthcare industry is growing rapidly, driven by aging populations, chronic disease prevalence, and rising healthcare spending. Innovations in precision medicine, gene therapy, and digital health are improving outcomes, though challenges include high R&D costs, strict regulations, and pricing pressures. Growth opportunities lie in emerging markets with expanding healthcare infrastructure, while key trends such as AI-driven personalized medicine, telehealth, and sustainable pharma solutions are reshaping the industry.
Analyst Conclusion
- Author say's: Europe accounted for a share of over 30% of the global market size of USD XX million and projected to expand at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
- The adult segment is boosting the market growth due to the second or third line of treatment for primary immune thrombocytopenia (ITP), romiplostim is recommended for adults.
- Romiplostim is recommended for paediatric patients who do not react to first-line treatment or who develop a steroid dependency due to its efficacy and safety features.
- The hospital held the highest romiplostim market revenue share in 2024.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
Frequently Asked Questions
★ Reviews
Rate this report
Europe Romiplostim Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Type | 250 μg/0.5 mL, 500 μg/1 mL |
|---|---|
| Application | Adults, Pediatric Patients |
| End-User | Hospitals, Clinics, Homecare |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| List of Competitors | AMGEN |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Top Players Ranking 2024
- 1.1.2 New Product Launch Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 AMGEN
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 R&D Investment (Subject to data availability)
- 1.2.1.4 Financials (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.1 AMGEN
- 1.1 Top Competitors Analysis
Chapter 2. Global Romiplostim Market Analysis
- 2.1 Global Romiplostim Market Analysis
- 2.2 Global Romiplostim Market Analysis by Type
- 2.3 Global Romiplostim Market Analysis by Application
- 2.4 Global Romiplostim Market Analysis by End-User
- 2.5 Global Romiplostim Market Analysis by Distribution Channel
Chapter 3. Europe Romiplostim Market Analysis
- 3.1 Europe Romiplostim Market Analysis
- 3.2 Europe Romiplostim Market Analysis by Country
- 3.3 Europe Romiplostim Market Analysis by Type
- 3.4 Europe Romiplostim Market Analysis by Application
- 3.5 Europe Romiplostim Market Analysis by End-User
- 3.6 Europe Romiplostim Market Analysis by Distribution Channel
- 3.7 Europe Romiplostim Market Analysis by Key Players
Chapter 4. United Kingdom Romiplostim Market Analysis
- 4.1 United Kingdom Romiplostim Market Analysis
- 4.2 United Kingdom Romiplostim Market Analysis by Type
- 4.3 United Kingdom Romiplostim Market Analysis by Application
- 4.4 United Kingdom Romiplostim Market Analysis by End-User
- 4.5 United Kingdom Romiplostim Market Analysis by Distribution Channel
- 4.6 United Kingdom Romiplostim Market Analysis by Key Players
Chapter 5. France Romiplostim Market Analysis
- 5.1 France Romiplostim Market Analysis
- 5.2 France Romiplostim Market Analysis by Type
- 5.3 France Romiplostim Market Analysis by Application
- 5.4 France Romiplostim Market Analysis by End-User
- 5.5 France Romiplostim Market Analysis by Distribution Channel
- 5.6 France Romiplostim Market Analysis by Key Players
Chapter 6. Germany Romiplostim Market Analysis
- 6.1 Germany Romiplostim Market Analysis
- 6.2 Germany Romiplostim Market Analysis by Type
- 6.3 Germany Romiplostim Market Analysis by Application
- 6.4 Germany Romiplostim Market Analysis by End-User
- 6.5 Germany Romiplostim Market Analysis by Distribution Channel
- 6.6 Germany Romiplostim Market Analysis by Key Players
Chapter 7. Italy Romiplostim Market Analysis
- 7.1 Italy Romiplostim Market Analysis
- 7.2 Italy Romiplostim Market Analysis by Type
- 7.3 Italy Romiplostim Market Analysis by Application
- 7.4 Italy Romiplostim Market Analysis by End-User
- 7.5 Italy Romiplostim Market Analysis by Distribution Channel
- 7.6 Italy Romiplostim Market Analysis by Key Players
Chapter 8. Russia Romiplostim Market Analysis
- 8.1 Russia Romiplostim Market Analysis
- 8.2 Russia Romiplostim Market Analysis by Type
- 8.3 Russia Romiplostim Market Analysis by Application
- 8.4 Russia Romiplostim Market Analysis by End-User
- 8.5 Russia Romiplostim Market Analysis by Distribution Channel
- 8.6 Russia Romiplostim Market Analysis by Key Players
Chapter 9. Spain Romiplostim Market Analysis
- 9.1 Spain Romiplostim Market Analysis
- 9.2 Spain Romiplostim Market Analysis by Type
- 9.3 Spain Romiplostim Market Analysis by Application
- 9.4 Spain Romiplostim Market Analysis by End-User
- 9.5 Spain Romiplostim Market Analysis by Distribution Channel
- 9.6 Spain Romiplostim Market Analysis by Key Players
Chapter 10. Sweden Romiplostim Market Analysis
- 10.1 Sweden Romiplostim Market Analysis
- 10.2 Sweden Romiplostim Market Analysis by Type
- 10.3 Sweden Romiplostim Market Analysis by Application
- 10.4 Sweden Romiplostim Market Analysis by End-User
- 10.5 Sweden Romiplostim Market Analysis by Distribution Channel
- 10.6 Sweden Romiplostim Market Analysis by Key Players
Chapter 11. Denmark Romiplostim Market Analysis
- 11.1 Denmark Romiplostim Market Analysis
- 11.2 Denmark Romiplostim Market Analysis by Type
- 11.3 Denmark Romiplostim Market Analysis by Application
- 11.4 Denmark Romiplostim Market Analysis by End-User
- 11.5 Denmark Romiplostim Market Analysis by Distribution Channel
- 11.6 Denmark Romiplostim Market Analysis by Key Players
Chapter 12. Switzerland Romiplostim Market Analysis
- 12.1 Switzerland Romiplostim Market Analysis
- 12.2 Switzerland Romiplostim Market Analysis by Type
- 12.3 Switzerland Romiplostim Market Analysis by Application
- 12.4 Switzerland Romiplostim Market Analysis by End-User
- 12.5 Switzerland Romiplostim Market Analysis by Distribution Channel
- 12.6 Switzerland Romiplostim Market Analysis by Key Players
Chapter 13. Luxembourg Romiplostim Market Analysis
- 13.1 Luxembourg Romiplostim Market Analysis
- 13.2 Luxembourg Romiplostim Market Analysis by Type
- 13.3 Luxembourg Romiplostim Market Analysis by Application
- 13.4 Luxembourg Romiplostim Market Analysis by End-User
- 13.5 Luxembourg Romiplostim Market Analysis by Distribution Channel
- 13.6 Luxembourg Romiplostim Market Analysis by Key Players
Chapter 14. Rest of Europe Romiplostim Market Analysis
- 14.1 Rest of Europe Romiplostim Market Analysis
- 14.2 Rest of Europe Romiplostim Market Analysis by Type
- 14.3 Rest of Europe Romiplostim Market Analysis by Application
- 14.4 Rest of Europe Romiplostim Market Analysis by End-User
- 14.5 Rest of Europe Romiplostim Market Analysis by Distribution Channel
- 14.6 Rest of Europe Romiplostim Market Analysis by Key Players
Chapter 15. Type Analysis
- 15.1 250 μg/0.5 mL
- 15.2 500 μg/1 mL
Chapter 16. Application Analysis
- 16.1 Adults
- 16.2 Pediatric Patients
Chapter 17. End-User Analysis
- 17.1 Hospitals
- 17.2 Clinics
- 17.3 Homecare
Chapter 18. Distribution Channel Analysis
- 18.1 Hospital Pharmacies
- 18.2 Retail Pharmacies
- 18.3 Online Pharmacies
Chapter 19. Qualitative Analysis (Subject to Data Availability)
- 19.1 Market Drivers
- 19.2 Market Restraints
- 19.3 Market Trends
- 19.4 Market Opportunity
- 19.5 Technological Road Map (Subject to Data Availability)
- 19.6 Product Life Cycle (Subject to Data Availability)
- 19.7 Customer and Buyer Behavior Analysis
- 19.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 19.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 19.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 19.7.4 Pricing, Affordability & Value Perception Analysis
- 19.7.5 Customer Segmentation & Demand Pattern Analysis
- 19.8 Industrial Chain Analysis (Subject to Data Availability)
- 19.8.1 Industry Chain Analysis
- 19.8.2 Manufacturing Cost Analysis
- 19.8.3 Supply Side Analysis
- 19.8.3.1 Raw Material Analysis
- 19.8.3.2 Raw Material Procurement Analysis
- 19.8.3.3 Raw Material Price Trend Analysis
- 19.9 PESTEL Analysis
- 19.9.1 Environmental Factors
- 19.9.2 Legal Factors
- 19.9.3 Technological Factors
- 19.9.4 Economic Factors
- 19.9.5 Political Factors
- 19.9.6 Social Factors
- 19.10 Porter’s Five Forces Analysis
- 19.10.1 Degree of Competition
- 19.10.2 Threat of Substitutes
- 19.10.3 Threat of New Entrants
- 19.10.4 Bargaining Power of Buyers
- 19.10.5 Bargaining Power of Suppliers
- 19.11 Patent Analysis (Subject to Data Availability)
- 19.12 ESG Analysis
- 19.13 Geopolitical Outlook
- 19.13.1 Global Power Realignment & Strategic Alliances
- 19.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 19.13.3 International Trade Relations & Market Access Environment
- 19.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 19.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 19.13.6 Technology Sovereignty & Digital Geopolitics
- 19.13.7 Strategic Implications for Investment, Growth & Market Entry
- 19.14 AI & Market Transformation
- 19.14.1 Competitive Landscape Disruption & Strategic Shifts
- 19.14.2 AI-Driven Transformation of Industry Value Chain
- 19.14.3 Evolution of Business Models & Revenue Streams
- 19.14.4 AI-Driven Product, Service & Innovation Transformation
- 19.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 20. Research Findings
- 20.1 Key Takeaways
- 20.2 Analyst Point of View
- 20.3 Assumptions and Acronyms
Chapter 21. Research Methodology and Sources
- 21.1 Primary Data Collection
- 21.1.1 Steps for Primary Data Collection
- 21.1.1.1 Identification of KOL
- 21.1.2 Backward Integration
- 21.1.3 Forward Integration
- 21.1.4 How Primary Research Help Us
- 21.1.5 Modes of Primary Research
- 21.1.1 Steps for Primary Data Collection
- 21.2 Secondary Research
- 21.2.1 How Secondary Research Help Us
- 21.2.2 Sources of Secondary Research
- 21.3 Data Validation
- 21.3.1 Data Triangulation
- 21.4 Data Representation
- 21.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Europe Romiplostim Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Pharma and Healthcare Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Europe Romiplostim Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the europe romiplostim market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
